Compare Crispr Therapeutics AG (CRSP) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Victoria's Secret & Co — how do they compare? Crispr Therapeutics AG trades at $50.51 (market cap $4.97B), while Victoria's Secret & Co trades at $84.5 (market cap $6.51B). The key difference: Victoria's Secret & Co is the larger of the two by market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | VSXY | |
|---|---|---|
Market Cap | $4.97B | $6.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $88.50 |
52-Week Low | $44.34 | $17.70 |
Enterprise Value | $3.32B | $9.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Victoria's Secret (VSXY) trades at $78.98, up 0.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and international growth momentum, particularly a 44.9% surge in Q1 2026 international sales, highlight operational improvements. The stock shows recovering profitability with a net income margin of 3.12% and robust ROE of 29.41%, though valuation metrics like a P/E of 31.47 suggest premium pricing relative to earnings.
The outlook remains positive with a consensus price target of $88.56 implying 12% upside, driven by innovation and global expansion. Risks include competitive pressures and reliance on margin recovery. Institutional sentiment is favorable with no sell ratings, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
